These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10894277)

  • 1. Effect of clinical events on plasma HIV-1 RNA levels in persons with CD4+ T-lymphocyte counts of more than 500 x 10(6) cells/l.
    Chapman LE; Green TA; Ahmed F; Parekh BS; Rimland D; Kaplan JE; Thompson MA; Folks TM
    AIDS; 2000 Jun; 14(9):1135-46. PubMed ID: 10894277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
    Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
    Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 x 10(6)/l.
    García F; Vidal C; Gatell JM; Miró JM; Soriano A; Pumarola T
    AIDS; 1997 Jan; 11(1):53-7. PubMed ID: 9110075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
    Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire.
    Nkengasong JN; Kalou M; Maurice C; Bile C; Borget MY; Koblavi S; Boateng E; Sassan-Morokro M; Anatole-Ehounou E; Ghys P; Greenberg AE; Wiktor SZ
    J Clin Microbiol; 1998 Sep; 36(9):2495-8. PubMed ID: 9705381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.
    Coakley EP; Samore MH; Gillis JM; Hughes MD; Hammer SM
    AIDS; 2000 Jun; 14(9):1147-53. PubMed ID: 10894278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
    Mellors JW; Muñoz A; Giorgi JV; Margolick JB; Tassoni CJ; Gupta P; Kingsley LA; Todd JA; Saah AJ; Detels R; Phair JP; Rinaldo CR
    Ann Intern Med; 1997 Jun; 126(12):946-54. PubMed ID: 9182471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
    Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
    AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
    Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire.
    Koblavi-Dème S; Kestens L; Hanson D; Otten RA; Borget MY; Bilé C; Wiktor SZ; Roels TH; Chorba T; Nkengasong JN
    AIDS; 2004 Feb; 18(3):413-9. PubMed ID: 15090792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
    Arnó A; Ruiz L; Juan M; Zayat MK; Puig T; Balagué M; Romeu J; Pujol R; O'Brien WA; Clotet B
    AIDS; 1998 May; 12(7):697-704. PubMed ID: 9619800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Paxton WB; Coombs RW; McElrath MJ; Keefer MC; Hughes J; Sinangil F; Chernoff D; Demeter L; Williams B; Corey L
    J Infect Dis; 1997 Feb; 175(2):247-54. PubMed ID: 9203644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.